Agne Vaitkeviciene

Agne Vaitkeviciene holds a BS in Molecular Biology (Vilnius University, Lithuania) and an MS in organ, tissue, and cell donation for Cell Therapy (University of Barcelona, Spain). Since 2006 she has been working in the field of cell therapy and ATMP manufacturing under GMP conditions. In 2013 Agne Vaitkeviciene co-founded a life science startup company and managed its activities in the field of advanced therapy medicinal product (ATMP) research and manufacturing as CEO until 2019. Since 2019 she has been actively involved as an expert in EU programs, such as IMI2, EIT Health Innostarts, and consults biotechnology companies in life science product development management. For the last 5 years, Agne has been actively involved in life science expert groups within Lithuanian governmental organizations such as the Innovation Agency of Lithuania and Invest Lithuania. Association LithuaniaBIO elected A. Vaitkeviciene as a Vice-President in 2019 (Re-elected in 2024) and delegated her responsibilities of coordinating foreign affairs and startup support activities within the Association. In 2020 - 2023 she was the Executive Director of LithuaniaBIO. Currently, Agne is responsible for overall Cureline Group activities in Lithuania, provides leadership for the ATMP CDMO program, and coordinates BD efforts in the EU region for member companies of the Cureline Group.